Addiction, Author Interviews, Cancer Research, Cannabis / 23.03.2024
Prior studies claiming to find a lethal cannabis-immunotherapy drug interaction riddled with errors
MedicalResearch.com Interview with:
[caption id="attachment_61470" align="alignleft" width="151"]
Dr. Piper[/caption]
Brian J. Piper, PhD
Associate Professor of Neuroscience
Geisinger Commonwealth School of Medicine
Scranton PA 18411
MedicalResearch.com: What is the background for this study?
Response: Many cancer patients use marijuana to treat pain, nausea, or anxiety, often without communicating this with their health care providers. Two observational studies (1, 2) from a single institution in Israel purporting to find a dangerous drug interaction between medical cannabis and immunotherapy have been cited hundreds of times, including by clinical practice guidelines.
The cannabinoid CB2 receptor is found on immune tissues so it is biologically possible that marijuana could make immunotherapies like nivolumab less effective. However, there were anonymous reports on PubPeer (3-5) of many irregularities in the data-analysis. If there were unappreciated differences on other important variables at baseline besides subsequent cannabis use, this could change the interpretation of these influential reports (1, 2). This investigation involved attempting to repeat and verify the data-analysis.
Dr. Piper[/caption]
Brian J. Piper, PhD
Associate Professor of Neuroscience
Geisinger Commonwealth School of Medicine
Scranton PA 18411
MedicalResearch.com: What is the background for this study?
Response: Many cancer patients use marijuana to treat pain, nausea, or anxiety, often without communicating this with their health care providers. Two observational studies (1, 2) from a single institution in Israel purporting to find a dangerous drug interaction between medical cannabis and immunotherapy have been cited hundreds of times, including by clinical practice guidelines.
The cannabinoid CB2 receptor is found on immune tissues so it is biologically possible that marijuana could make immunotherapies like nivolumab less effective. However, there were anonymous reports on PubPeer (3-5) of many irregularities in the data-analysis. If there were unappreciated differences on other important variables at baseline besides subsequent cannabis use, this could change the interpretation of these influential reports (1, 2). This investigation involved attempting to repeat and verify the data-analysis.
Dr. Cortese[/caption]
Marianna Cortese, MD, PhD
Senior Research Scientist
Dr. Fangqun Yu[/caption]
Dr. Fangqun Yu PhD
Senior Research Faculty
Atmospheric Sciences Research Center University
Albany, State University of New York
Dr. Arshad Nair[/caption]
Dr. Arshad Arjunan Nair PhD
Postdoctoral Associate
Atmospheric Sciences Research Center
University at Albany, State University of New York
Skilled
Dr. Magruder[/caption]
Matthew Magruder, MD PGY3
Orthopaedic Residency Program
Department of Orthopaedic Surgery and Rehabilitation
Maimonides Medical Center
MedicalResearch.com: What is the background for this study?
Response: The prevalence of obesity and diabetes mellitus has reached epidemic proportions. Approximately 37.3 million people in the United States, accounting for 11.3% of the total population, have diabetes, and 100.1 million, or 41.9%, of all US citizens are obese. Furthermore, these numbers are only projected to increase in the coming decades. This is an issue for orthopaedic surgeons because diabetes and obesity have consistently been demonstrated to be risk factors for complications following total joint replacements, especially total hip replacements. Therefore, we are in desperate need of new and more effective tools in mitigating the risk of poor outcomes in our joint replacement patients.
Semaglutide, and other GLP-1 agonists, are potentially a new tool that can be used to help decrease the risks following joint replacement surgery. Initially a medication to treat diabetes, semaglutide has recently been approved by the FDA to treat obesity as well, as randomized controlled trials have consistently demonstrated significant weight loss with minimal side effects. The purpose of our study was to see what effect the use of semaglutide had on total hip arthroplasty patient outcomes.
Dr. Akefe[/caption]
Isaac O Akefe DVM, PhD
Clem Jones Centre for Ageing Dementia Research
Queensland Brain Institute
The University of Queensland St Lucia
Academy for Medical Education, Medical School
Brisbane QLD Australia
MedicalResearch.com: What is the background for this study?
Response: The brain is the body’s fattiest organ, with fatty compounds called lipids making up 60% of its weight. Fatty acids are the building blocks of a class of lipids called phospholipids.
In our study, we first showed that levels of saturated fatty acids increase in the brain during neuronal communication and long-term memory formation, but we didn’t know what was causing these changes.
It is your lifestyle that determines your blood pressure levels. Your nutritional intake and the level of activity have a significant part as well.
Wilson N. Merrell
Ph.D. Student
Dr. Li Li[/caption]
Li Li, M.D., Ph.D., M.P.H
Walter M. Seward Professor
Chair of Family Medicine
Director of population health
University of Virginia School of Medicine
Editor-in-chief of The BMJ Family Medicine
Dr. Li joined the U.S. Preventive Services Task Force in January 2021
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Speech and language delays and disorders can be challenging for children and their families and can lead to difficulties with reading and writing as children grow up.
The Task Force looked at the evidence on screening for speech and language delays and, unfortunately, there is not enough evidence to tell us whether or not it is helpful to screen all children 5 years old and younger for speech and language delays and disorders.
Dr. Di Ciano[/caption]
Patricia Di Ciano, PhD
Lauren C. Davis, MBS
Department of Medical Education
Geisinger Commonwealth School of Medicine
Scranton, PA 19409
MedicalResearch.com: What is the background for this study?
Response: Financial conflicts of interest (COIs) resulting from ties between academia and industry have been under scrutiny for their potential to hinder the integrity of medical research. COIs can lead to implicit bias, compromise the research process, and erode public trust (1-6). The American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders (DSM), standardizes symptom criteria and codifies psychiatric disorders. This manual contributes to the approval of new drugs, extensions of patent exclusivity, and can influence payers and mental health professionals seeking third-party reimbursements. Given the implications of the DSM on public health, it is paramount that it is free of industry influence. Previous research has shown a high prevalence of industry ties among panel and task force members of the DSM-IV-TR and DSM-5, despite the implementation of a disclosure policy for the DSM-5 (7,8). This study (9) determined the extent and type of COIs received by panel and task-force members of the DSM-5-TR (2022) (10). As the DSM-5-TR did not disclose COI, we used the Center for Medicare and Medicaid Services Open Payments (OP) database (11) to quantify them.